{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:40:03Z","timestamp":1793176803541,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023368","name":"Eisai Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clgc.2023.12.010","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T21:19:49Z","timestamp":1703107189000},"page":"394-401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-7687","authenticated-orcid":false,"given":"Viktor","family":"Gr\u00fcnwald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2778-3108","authenticated-orcid":false,"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.12.010_bib0001","series-title":"StatPearls [Internet]","article-title":"Renal cell cancer","author":"Garfield","year":"2022"},{"key":"10.1016\/j.clgc.2023.12.010_bib0002","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol"},{"key":"10.1016\/j.clgc.2023.12.010_bib0003","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/cam4.574","article-title":"Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras","volume":"5","author":"Li","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.clgc.2023.12.010_bib0004","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.12.010_bib0005","unstructured":"Keytruda 25 mg\/mL concentrate for solution for infusion [summary of product characteristics]. Haarlem, The Netherlands: Merck Sharp & Dohme B.V.; 2023."},{"key":"10.1016\/j.clgc.2023.12.010_bib0006","unstructured":"Kisplyx 4 mg and 10 mg hard capsules [summary of product characteristics]. Frankfurt am Main, Germany: Eisai GmbH; 2023."},{"key":"10.1016\/j.clgc.2023.12.010_bib0007","unstructured":"Lenvima (lenvatinib) [prescribing information]. Nutley, NJ, USA: Eisai Inc.; 2022."},{"key":"10.1016\/j.clgc.2023.12.010_bib0008","author":"Keytruda (pembrolizumab) [prescribing information]","year":"2023"},{"key":"10.1016\/j.clgc.2023.12.010_bib0009","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2021.04.042","article-title":"The 2021 updated European Association of Urology Guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care","volume":"80","author":"Bedke","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.12.010_bib0010","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2147\/PPA.S132894","article-title":"Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study","volume":"11","author":"Tan","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"2 Suppl","key":"10.1016\/j.clgc.2023.12.010_bib0011","article-title":"Analysis of real-world treatment adherence in a cohort of 2,395 patients with metastatic renal cell carcinoma (mRCC) [abstract]","volume":"34","author":"Margolis","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.12.010_bib0012","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2407-11-105","article-title":"Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy","volume":"11","author":"Porta","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2023.12.010_sbref0013","series-title":"ICH E2A Clinical safety data management: definitions and standards for expedited reporting","year":"1995"},{"key":"10.1016\/j.clgc.2023.12.010_bib0014","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/oncolo\/oyac269","article-title":"Characterization and management of adverse reactions from the CLEAR study in advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab","volume":"28","author":"Motzer","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2023.12.010_bib0015","series-title":"StatPearls [Internet]","article-title":"Tyrosine Kinase Inhibitors","author":"Thomson","year":"2023"},{"key":"10.1016\/j.clgc.2023.12.010_bib0016","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2023.12.010_sbref0017","series-title":"Common terminology criteria for adverse events (CTCAE). Version 4.0","year":"2010"},{"key":"10.1016\/j.clgc.2023.12.010_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102333","article-title":"Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: a review","volume":"103","author":"McGregor","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2023.12.010_bib0019","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41416-020-0949-9","article-title":"Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events","volume":"123","author":"Gr\u00fcnwald","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2023.12.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2023.12.010_bib0021","unstructured":"The University of Texas M. D. Anderson Cancer Center. Brief Fatigue Inventory, https:\/\/www.ons.org\/sites\/default\/files\/2017-06\/BriefFatigueInventory_English_1.pdf; 1999 [accessed 1 August 2023]."},{"key":"10.1016\/j.clgc.2023.12.010_bib0022","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1089\/thy.2014.0028","article-title":"Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement","volume":"24","author":"Jonklaas","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.clgc.2023.12.010_bib0023","doi-asserted-by":"crossref","first-page":"405","DOI":"10.12998\/wjcc.v7.i4.405","article-title":"Immune checkpoint inhibitor-induced colitis: a comprehensive review","volume":"7","author":"Som","year":"2019","journal-title":"World J Clin Cases"},{"issue":"1","key":"10.1016\/j.clgc.2023.12.010_bib0024","first-page":"1","article-title":"Clinical Practice Guidelines for acute kidney injury","volume":"2","author":"Kidney Disease Improving Global Outcomes (KDIGO)","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.clgc.2023.12.010_bib0025","first-page":"479","article-title":"Diagnosis and management of nephrotic syndrome in adults","volume":"93","author":"Kodner","year":"2016","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clgc.2023.12.010_bib0026","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clgc.2023.12.010_bib0027","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00134-018-5223-8","article-title":"Angiotensin inhibition in patients with acute kidney injury: Dr. Jekyll or Mr. Hyde?","volume":"44","author":"Joannidis","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.clgc.2023.12.010_bib0028","first-page":"e201","article-title":"Treatment of oral mucositis due to chemotherapy","volume":"8","author":"Chaveli-L\u00f3pez","year":"2016","journal-title":"J Clin Exp Dent"},{"key":"10.1016\/j.clgc.2023.12.010_bib0029","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0300891620915786","article-title":"Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial","volume":"106","author":"Porta","year":"2020","journal-title":"Tumori"},{"key":"10.1016\/j.clgc.2023.12.010_bib0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CAD.0000000000001356","article-title":"The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma","volume":"34","author":"Buti","year":"2023","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clgc.2023.12.010_bib0031","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/COC.0000000000000991","article-title":"The impact of concomitant proton pump inhibitors therapy on clinical outcome of cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"46","author":"Cao","year":"2023","journal-title":"Am J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:28:28Z","timestamp":1793176108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323002768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1558767323002768"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.12.010","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}